Osteoporosis, alveolar bone loss, and drug development.
Wynn
R L
RL
D000368:Aged; D019386:Alendronate / Q000627:therapeutic use; D016301:Alveolar Bone Loss / Q000188:drug therapy* / Q000378:metabolism; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D045424:Complex Mixtures; D003802:Dentifrices / Q000627:therapeutic use; D015232:Dinoprostone / Q000096:biosynthesis; D015195:Drug Design; D005260:Female; D005459:Fluorides; D005480:Flurbiprofen / Q000627:therapeutic use; D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis; D020910:Ketorolac / Q000627:therapeutic use; D008875:Middle Aged; D009067:Mouthwashes / Q000627:therapeutic use; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D012824:Silicic Acid; D013654:Taurine / Q000627:therapeutic use; D016388:Tooth Loss / Q000517:prevention & control; D014100:Toothpastes; D014260:Triclosan
D000894:Anti-Inflammatory Agents, Non-Steroidal; D045424:Complex Mixtures; D003802:Dentifrices; D007375:Interleukin-1; D009067:Mouthwashes; D014100:Toothpastes; C546060:hydrated silica gel-based toothpaste; D012824:Silicic Acid; D013654:Taurine; D014260:Triclosan; D005480:Flurbiprofen; D015232:Dinoprostone; D005459:Fluorides; D019386:Alendronate; D020910:Ketorolac